Healthcare: Are These Beaten-Down Clinical-Stage Biotechs Buys?
Industry Focus - Un pódcast de The Motley Fool
Categorías:
Geron shares tumbled after J&J jilted them and Omeros shares fell sharply following a clinical-trial update. Should you avoid these stocks, or are they bargain bin stocks worth buying? GERN OMER INCY
